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Abstract
Dengue remains the most common vector-transmitted disease in the world despite enor-
mous prevention and control efforts by endemic countries and regions. Today, after decades 
of research, public health programs contemplate as part of the intervention to control the dis-
ease, a safe and effective vaccine against dengue. In this chapter, we review general principles 
for developing a safe and efficacious vaccine against dengue virus, the current vaccine candi-
dates approved and under research, and the roadmap for the introduction of a new dengue 
vaccine, based on the procedures, carried out by Mexico, for the licensure and eventual adop-
tion of CYD-TDV vaccine, which concluded with Mexico becoming the first country in 
the world to grant licensure to a Dengue vaccine in December of 2015. Finally, we discuss the 
rationale for the adoption of dengue vaccines a public health policy and the paradigm shift 
required for the efficient adoption of vaccines in low- and middle-income countries.
Keywords: dengue control, vaccine, prevention, public health
1. Introduction
Vaccination is one of the most successful preventive measures in public health; its relevance 
for the prevention and control of infectious diseases is beyond any doubt. Vaccines have been 
paramount in the eradication of human and animal diseases such as smallpox [1] and rinder-
pest [2] and have been a main driver for the eradication efforts of other diseases (Table 1).
“The impact of vaccination on the health of the world’s people is hard to exaggerate. With the excep-
tion of safe water, no other modality has had such a major effect on mortality reduction and population 
growth”
Stanley Plotkin
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licenses/by/3.0), w ich permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
As we all know, in public health, disease eradication through vaccination is an ultimate goal; 
nonetheless, this is not the only benefit of vaccines. Well-documented advantages such as elimi-
nation of diseases, control of mortality, morbidity and complications of disease are positive 
impacts of immunizations. Additional benefits can be attributed to vaccines such as mitigation 
of disease severity, protection of unvaccinated population through herd immunity, prevention 
of antibiotic resistance, extension of life expectancy, enhancement of equality and empowerment 
of vulnerable populations. These effects are perhaps not as recognizable as disease eradication, 
but they have certainly shaped the health profile of entire populations [4].
Vector-transmitted diseases (VTDs) are a heterogeneous group of human illnesses caused by 
viral, bacterial and parasitic agents. Unlike many other infections in which transmission occurs 
directly between humans, VTD transmission cycles require the involvement of different arthro-
pods such as mosquitoes, ticks, fleas, flies and kissing bugs, which work as vectors by carrying 
pathogens from humans to humans. In some VTDs like malaria, zika or dengue, arthropods 
and humans are the only components of the cycles; however, other VTDs like Chagas disease or 
Yellow fever are also zoonoses, which means that their transmission cycles include intermediate 
hosts, usually mammals. The more complex these cycles are, the more difficult VTDs control is 
[5], since more interventions are required to interrupt transmission. As an example, lymphatic 
filariasis is potentially eradicable since it has few vectors, and there is a non-expensive and 
effective treatment, which administered regularly to population at risk in large endemic areas 
ensures the interruption of transmission independently of vector circulation. Chagas disease, on 
the other hand, is considered non-eradicable since it has multiple vectors and hosts, it is difficult 
to diagnose, and the treatment is not well tolerated by most patients.
To date, prevention and control of VTDs, especially those transmitted by mosquitoes, rely 
mostly on vector control strategies, usually insecticide spraying and physical denial of vec-
tor’s ecological niches. In the case of dengue, preventive measures include focal approaches 
with different schemes of insecticide use for indoor and outdoor settings aimed at larvae and 
adults, and the physical removal or destruction of mosquito breeding sites. For outbreak con-
trol, the same two interventions are usually applied with intensive schemes. For other VTDs, 
Disease Main public health measures Conclusion of the International Task Force 
for Disease Eradication
Dracunculiasis Water sanitation, vector control, 
surveillance and contention
Eradicable
Lymphatic filariasis Pharmacological treatment, vector control Potentially eradicable
Measles Vaccination Potentially eradicable
Mumps Vaccination Potentially eradicable
Poliomyelitis Vaccination Eradicable
Rubella Vaccination Potentially eradicable
Taeniasis/cysticercosis Improved sanitation, pharmacological 
treatment, vaccination of cattle
Potentially eradicable
Table 1. Candidate diseases for eradication. Modified from Ref. [3].
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such as malaria, early identification and diagnosis of cases have proven to be an efficacious 
measure [6], but for a number of reasons such as cost, lack of point-of-care diagnostic tools 
and complicated logistics, this is not as applicable for dengue. Unfortunately, few vaccines 
have been developed successfully for this group of diseases, and nevertheless, examples such 
as the yellow fever vaccine show that, although challenging, vaccines can be essential for 
achieving or improving disease control. Thanks to the introduction of the vaccine, urban yel-
low fever is rare, and sylvatic yellow fever has been under control for decades.
Dengue virus (DENV) infection causes a broad spectrum of clinical manifestations ranging 
from asymptomatic infection to life-threatening severe dengue [7]. Each year, up to 390 mil-
lion infections worldwide, resulting in about 96 million clinical cases, represent a huge bur-
den of disease for health systems in endemic areas [8]. Although most cases are benign and 
only a minor fraction of these develop severe disease, the number of infections every year 
and consequently the number of severe forms of dengue continue to increase despite current 
vector control measures since there is no specific preventive measure focused on the host. The 
expenditure on vector control represents an enormous burden and a threat to health systems 
in low- and middle-income countries [9].
Climate change, urbanization and other anthropogenic factors facilitate transmission of den-
gue and other VTDs [10]. Current vector control strategies have not, with very few exceptions, 
provided the expected results in diminishing or stabilizing dengue transmission for long peri-
ods [11]. Case identification is not currently feasible and before the availability of dengue vac-
cines, no other preventive option existed for the host. Considering these perspectives, dengue 
vaccines are more than ever a true necessity for improving the health of the millions that 
inhabit dengue endemic regions.
2. Development of vaccines against dengue
Dengue virus (DENV) belongs to the Flaviviridae family. Vaccines against members of this 
family such as the yellow fever virus (YFV) [12], the Tick-borne Encephalitis virus (TBEV) [13], 
and the Japanese Encephalitis virus (JEV) [14] have been successfully developed; nonetheless, 
a reliable and efficacious vaccine against dengue remained an elusive goal for decades.
Some characteristics of the dengue virus and the disease it causes constitute a great challenge 
for the development of a dengue vaccine. Some of those related to the agent are the geno-
type divergence, which contrary to other members of the Flaviviridae family, is so wide that 
it translates into notable serotype divergence [15–17], therefore making difficult to identify 
immunogenic proteins that are widely conserved among serotypes. In the case of flaviviruses, 
the main immunogenic protein is located in the envelope (E protein), which as we will review 
below, it is the basis for the development of most of vaccine candidates against dengue.
Another important challenge lies in the pathophysiology of severe dengue, which is strongly 
associated with previous exposure to the dengue virus. A secondary exposure after initial 
“priming” is capable of triggering an exaggerated immune response characterized by a cyto-
kine storm, which contributes to impaired endothelial function and plasma leakage as its 
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main pathologic characteristic. Because of this, any vaccine developed against dengue needs 
to achieve a balance between being protective enough to prevent the disease and being suf-
ficiently safe to avoid a pathologic immune response after priming [18].
An additional difficulty arises with the fact that a natural dengue infection elicits two types of 
antibodies. One type of antibodies is specific against the infecting serotype; these are usually 
long-lasting and with neutralizing capacity. The other type is cross-reactive to other sero-
types, short lasting and non-neutralizing. Short lasting, non-neutralizing antibodies contrib-
ute to limit dengue epidemics and the number of serotypes that cause outbreaks. It is believed 
that in the long term, these non-neutralizing antibodies might play a role in the pathophysiol-
ogy of dengue by facilitating the infection of larger number of cells during secondary expo-
sures to the virus, a phenomenon called “antibody-dependent enhancement,” or ADE [19]. 
Apparently, this phenomenon is not exclusive of dengue virus infections and has only been 
demonstrated in vitro; however, its real contribution to dengue pathophysiology is still under 
debate. Nonetheless, the risk of ADE needs to be taken into account when developing vaccines 
against dengue [20].
Based on these biological characteristics, it is desirable that any dengue vaccine developed be 
capable of immunizing simultaneously against each of its four known serotypes. Also, in order 
to avoid natural infections that might trigger secondary pathologic responses, the vaccine 
should be administered in a minimum-dose scheme and in a short period [21, 22]. Simulation 
studies have shown that even vaccines that do not elicit complete protection against all sero-
types and require multiple-dose schemes would be valuable tools in the medium and long 
terms, since their positive impacts exceed the theoretical potential negative effects [23].
Table 2 shows a list of the most relevant vaccines against dengue, currently approved and 
under development. Although not a comprehensive list, we can observe the different types 
of vaccines, and as discussed below, their particular advantages and disadvantages. It is 
expected that in the near future, many of these vaccines will become available and will be 
introduced as part of national dengue control strategies in endemic countries and regions.
Vaccine Manufacturer Type Serotypes included
CYD-TVD Sanofi – Pasteur Recombinant live-attenuated chimeric. PrM/E 
proteins cloned into a 17D YFV backbone
All four
DENVax Takeda Live attenuated. Recombinant PM/E proteins 
from DENV-1, DENV-3 and DENV-4 cloned 
into live-attenuated DENV-2
All four
TV003/TV005 NIAID/Butantan Institute Live-attenuated admixture of mutated and 
chimeric viruses
All four
TDENV PIV GSK Purified, formalin-inactivated viruses All four
V180 Merck Recombinant subunit. Truncated E protein 
from each DENV serotype
All four
TVDV NMRC DNA. Plasmids encoding PrM/E genes All four
Table 2. Vaccines currently used or under development against dengue [18, 22, 24, 25].
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In general, live-attenuated vaccines are produced with viable viruses that have been modi-
fied from wild-type pathogenic viruses into less virulent or attenuated versions, which are 
unable to produce severe disease. They have the advantage of being capable of infecting cells 
and replicating, eliciting strong, long-term immune responses similar to natural infections. 
However, since these vaccines contain live viruses, reversion to pathogenic forms is always a 
possibility; therefore, surveillance is necessary to ensure the safety of the vaccine. These vac-
cines cannot be administered to pregnant women or immunosuppressed individuals [26]. The 
yellow fever and Japanese Encephalitis vaccines belong to this group.
Inactivated vaccines are produced by exposing a pathogenic agent to chemicals, heat, or 
radiation in a process called inactivation. These vaccines are preferred over live-attenuated 
vaccines due to the absence of risks such as reversion of virulence, or limitations on its usage 
in selected population groups such as pregnant women and immunosuppressed individuals. 
Although they are generally very stable, sometimes, the inactivation process alters the struc-
ture of the pathogens, and possibly the immunogenicity of the viral proteins, diminishing its 
efficacy to elicit a protective immune response. Given the alteration caused by the inactivation 
process, the viruses from these vaccines are unable to replicate, and therefore, the viral pro-
teins must be highly immunogenic on their own. Otherwise, the vaccine formulation needs to 
be added with a booster or adjuvant to increase its immunogenicity. The formalin-inactivated 
TDENV-PIV dengue vaccine under development belongs to this group [26].
Subunit vaccines are similar to inactivated vaccines, but they are formulated with incomplete 
agents, usually proteins form the original pathogenic strain. Since they are not whole patho-
gens, they cannot replicate, and the risk of reversion is absent, but they also lack the immu-
nogenicity of whole pathogens. Therefore, the trick is to reach an acceptable immunogenic 
capability with truncated proteins that are unable to be infectious [26]. The V180 dengue 
vaccine is being formulated using a subunit of the E protein.
Recombinant vector vaccines, also known as chimeric vaccines, are based on attenuated 
viruses or microbes to introduce DNA from a pathogenic agent mimicking a natural infec-
tion and stimulating the immune system. The CYD-TDV dengue vaccine is a live-attenuated 
chimeric tetravalent vaccine constructed by cloning DENV Pre-M and E genes into a yellow 
fever Virus 17D strain backbone and belongs to this group [27]. Phase 3 clinical trials have 
demonstrated the vaccine’s efficacy in preventing severe forms of dengue and admissions to 
hospital [28–30]. WHO has published a position paper describing the recommended proce-
dures and conditions under which this vaccine is to be used by the international community 
[31]. To date, this is the only existing approved vaccine in the world. It was first licensed in 
Mexico in December of 2015 [32], and by late 2016, 12 additional countries from Latin America 
and Southeast Asia have also granted licensure to CYD-TDV.
Finally, DNA vaccines are theoretically the safest type of vaccines. They are formed by nucleic 
acids that encode fragments of the original pathogenic agent that are administered directly into the 
cells in order to produce immunogenic proteins that provide a protective immune response against 
infection. Nonetheless, the immune response that these vaccines produce is usually weak, and 
although promising, they still are in experimental phases [26]. This strategy is used in the TVDV 
dengue vaccine, which relies on fragments of DENV prM/E proteins expressed by a plasmid vector.
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3. The vaccine introduction process
Traditionally, the introduction of vaccines in low- and middle-income countries (LMIC) 
occurs years or even decades after they have been introduced in high-income countries. With 
very few exceptions, vaccines are usually developed, tested and adopted according to the 
public health needs of high-income countries. LMICs seldom participate in the vaccine devel-
opment process and only uptake products already tested in developed markets.
Because of this passive behavior, it takes a long time for public health officials in LMICs to 
incorporate new vaccines since there is a tendency to wait for licensure, introduction and 
phase 4 studies in high-income countries before beginning the introduction process. This 
delay in the adoption of innovation in public health technologies causes unnecessary suffer-
ing for populations in need of such scientific advances to address their health needs.
Recent events such as the emergence of infectious diseases like zika and, chikungunya in 
the Americas, or the re-emergence of Ebola in Africa have exposed the weaknesses of public 
health systems, and the need to change this passive behavior in order to accelerate access 
to the benefits provided by vaccines for those who need them the most [33]. The aim is for 
LMICs to participate in all phases of vaccine development, from their theoretical conception 
to all levels of clinical trials, and then to reduce the elapsed time between the moment a safe 
and efficacious vaccine is ready for commercialization and the moment the vaccine is licensed 
and eventually adopted.
As an effort to promote the early adoption of vaccines in LMICs, the authors have pushed 
forward for a paradigm shift in the introduction of new vaccines by designing and support-
ing the implementation of a new strategy for vaccine introduction based on scientific and 
technical analyses, and the accompaniment of public health authorities in the process. The 
aim of this strategy is to modify the general attitude toward vaccine introduction by involving 
all relevant actors (government, academia, industry, National Regulatory Agencies, etc.) in a 
proactive and anticipatory exercise.
These efforts led to the development of a roadmap for the Introduction of New Vaccines that 
has been instrumented in Mexico for the incorporation of the new dengue vaccine. In the fol-
lowing section, we will describe the process followed to promote the early adoption of these 
novel vaccines as a public health policy in the country.
3.1. A roadmap for the introduction of a dengue vaccine
It is necessary to recognize that the process for the introduction of any vaccine does not begin 
with the development of a candidate molecule by researchers. This path actually starts with 
the daily activities of epidemiologists and public health workers in the field, which generate 
and provide reliable epidemiological information, thus revealing health needs characterized 
as disease cases, fatalities, stress to health systems or any other negative impact. In Mexico, 
as in many other countries, dengue has become a major challenge for public health in the last 
three decades causing large outbreaks, mortality, and an increase in the demand of health 
services across the country. Its seasonal and oscillatory behavior makes it difficult to predict 
when or where there will be outbreaks in order to anticipate control interventions.
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As vaccine candidates developed by the pharmaceutical industry began to show results from 
early clinical trials in recent years suggesting the availability of a safe and efficacious dengue 
vaccine in the short term, the authors presented to Mexican Health authorities a roadmap 
proposal for the eventual adoption of such technologies into the Mexican context. This road-
map includes a series of well-defined steps to be followed in anticipation to the licensure of 
the vaccine by the National Regulatory Agency in order to be ready for early implementation.
To lead the anticipatory exercise, an independent, multidisciplinary body of experts, called 
Mexican Dengue Expert Group (MDEG), was specifically convened. The MDEG included rep-
resentatives from academic and research institutions, public health authorities and represen-
tatives of the private and social sectors (Figure 1).
The objectives of the MDEG were to analyze and discuss all relevant aspects related to the 
possibility of the introduction in Mexico of the different vaccines under development and 
also to evaluate their potential impact on the disease epidemiology and the implications on 
the National Immunizations and Vector-Borne Disease Prevention and Control Programs, in 
order to issue recommendations to the Mexican Public Health Authorities.
The roadmap was presented to and accepted by national health authorities in Mexico, which 
accepted the MDEG as the group that would officially lead the process.
The specific topics discussed and analyzed by the MDEG were epidemiological data and bur-
den of disease: economic and financial aspects, operational and logistical issues, legal and 
regulatory aspects, strategic communications and clinical issues (Table 3). All these elements 
were reviewed taking into account the available evidence on safety and efficacy of the different 
candidate vaccines.
Figure 1. General roadmap for the introduction of a new dengue vaccine.
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The roadmap included two phases. The first phase reviewed the existing evidence in order to 
analyze vaccine developments and the feasibility and requirements for the eventual adoption 
of such vaccines into the dengue control and immunization programs. This phase took place 
between 2011 and 2013 and resulted in an initial set of recommendations for the introduc-
tion of the vaccine in Mexico [34]. Evidence from a number of vaccine candidates in light of 
national epidemiological data quickly demonstrated that the adoption of any dengue vaccine 
in the future would require major improvements in many aspects.
With regard to epidemiological surveillance, the MDEG identified the need for strengthening 
the capacity of surveillance systems, networks, classification of cases and diagnostic proto-
cols. Evidence of differential vaccine efficacy against the four dengue serotypes requires the 
improvement of virological typing and mathematical modeling capabilities to correctly evalu-
ate the impact of vaccine introduction on the population.
Subgroup of epidemiological information and disease burden
I. To define geographic areas for the introduction of a vaccine.
II. To define the target population.
III. To establish impact scenarios of the vaccination scheme.
Subgroup of economic and financial aspects
IV. To generate cost-benefit and cost-effective studies using modeling tools.
V. To define the budgetary requirements for the introduction of the vaccine into the country.
Subgroup of operational aspects
VI. To analyze the age groups for the application of the immunization scheme.
VII. To generate strategies and scenarios for vaccine application depending on the selected target population.
VIII. To discuss the relevance of strengthening the immunization information system in order to accurately measur-
ing the coverage of the target population.
IX. To analyze the impact in the cold chain caused by the introduction of a new vaccine.
X. To develop the operational training strategy for the Universal Vaccination Program in the areas of vaccine 
introduction.
Subgroup of legal and regulatory aspects
XI. To ensure the readiness of the registration and licensure procedures for the vaccines.
XII. To orchestrate an automated pharmacosurveillance system to ensure the monitoring of adverse events follow-
ing immunization (AEFI’s) attributable to the vaccine introduction.
Subgroup of strategic communication
XIII. Generate strategies that allow the appropriate communication on the rationale behind a Dengue vaccine in-
troduction to all relevant groups.
XIV. Develop specific communication channels for the new vaccine’s target population.
XV. Ensure that messages on the general population inform on the importance of strengthening vector control, 
and the role of the new vaccine as part of an integral strategy, not as a substitute of prevention and control 
activities.
Subgroup of clinical aspects
XVI. Analyze the elements of clinical care in patients with Dengue that might result affected by the introduction 
of the vaccine.
XVII. Strengthen the health personnel capabilities in clinical scenarios for detecting and reporting AEFI.
XVIII. Strengthen the clinical personnel capacity for differential diagnosis of regional febrile diseases related to DF.
This figure describes the specific objectives from each working subgroup.
Table 3. Specific objectives for each subgroup in the Dengue Mexican Expert Group.
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Economic and financial issues were discussed as a basic element in the context of constrained 
resources such as those prevalent in LMICs; therefore, it was necessary to establish common 
methodologies for economic burden studies and those for cost-effectiveness of preventive and 
control interventions.
The analyses concerning the operational aspects required for the introduction of new vaccines 
concluded on the necessity for establishing baseline measurements to evaluate impact, feasi-
bility of population selection from endemic areas with high risk of transmission and adoption 
of vaccines using currently available strategies in the country.
Regulatory issues were not essential before the beginning of the registration process; none-
theless, the MDEG was able to continuously review industry data, particularly results from 
phase II and III studies and also to participate in the development of post marketing surveil-
lance systems that would be necessary in the event of the vaccine licensure.
Finally, social communication and health promotion had to be addressed in order to transmit 
clear messages on the safety and efficacy of vaccines, the implementation of vaccines into 
current integrated strategies for dengue control and not as an isolated intervention, and more 
important to clarify the regionalized strategy for these vaccines in contrast to universal vac-
cination schemes used regularly in the country.
After the first phase, the MDEG produced the following recommendations.
I. Strengthen epidemiologic, entomologic and virological surveillance and obtain data 
necessary for impact modeling of dengue vaccine introduction.
II. Carry out studies of the economic burden of dengue in Mexico, necessary for cost-bene-
fit and cost-effectiveness analyses to support financial decisions.
III. Introduce the vaccine as soon as it becomes available.
IV. Invite potential vaccine producers to engage with the national regulatory authority to 
facilitate registration and licensing procedures.
V. Integrate the immunization schedule defined by the National Vaccination Council of 
Mexico and approved by COFEPRIS with pre-existing National Health Weeks.
VI. Define vaccination age groups according to epidemiologic risk and produ cers’ recommen-
dations.
VII. Collect data to support national information campaigns to facilitate introduction.
The second phase of the roadmap began in 2015 when the results from the phase 3 studies 
of the CYD-TDV vaccine were published and the licensure process for this vaccine by the 
Mexican National Regulatory Agency (COFEPRIS—National Commission for the Protection 
of Health Risks) began. The availability of these results raised the necessity for the MDEG to 
review the data derived from the CYD-TDV phase 3 trials [30], focusing on this occasion, on 
the analysis of the feasibility of introducing the vaccine as a public policy, considering the 
special characteristics of dengue as a disease and those of the vaccine as a preventive tool. As 
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part of the work carried out in this phase, it was decided to incorporate an external perspec-
tive by extending an invitation to the Partnership for Dengue Control (PDC), an international 
organization integrated by world-class experts on dengue with the aim of supporting global 
elimination efforts for the disease, to participate in the proceedings. PDC experts participated 
actively in the discussions and issued specific recommendations that were included in the 
final document prepared by the MDEG.
After deep analysis of the available evidence, the MDEG presented to the Mexican Ministry of 
Health its final recommendations for the introduction of the dengue CYD-TDV vaccine [35]. 
The MDEG reiterated its support for the adoption of the vaccine and developed the criteria 
shown in Table 4.
In parallel, and recognizing the existence of a viable vaccine candidate, international institu-
tions such as the World Health Organization began similar exercises, and in April of 2015, the 
Strategic Advisory Group of Experts on Immunization (SAGE) issued the first recommenda-
tions on the use of Dengue vaccines [36], which were followed by the emission of WHO’s 
Position paper on dengue vaccination in July of 2016 [31]. These official documents  recognize 
the availability of a licensed dengue vaccine and establish the conditions under which the 
introduction of CYD-TDV is to be considered. As observed, MDEG’s recommendations are 
fully consistent with those issued by WHO, which consequently validate this innovative 
approach to vaccine introduction.
1. The following epidemiological criteria must be considered for the introduction of the new dengue vaccine into 
municipalities. At least four out of the six following conditions must be met:
a. Cumulative incidence above national mean during at least one of the last 5 years.
b. Notification of dengue confirmed cases for at least 20 continuous weeks in the immediate prior year.
c. Annual proportion of severe cases equal or above 1%, considering the total reported cases of severe dengue 
and dengue with warning signs.
d. At least one confirmed dengue fatality during the last 5 years.
e. Co-circulation of at least two serotypes, and/or circulation of serotype 3 and/or 4.
f. Seroprevalence above 60%.
2. To apply the vaccine on population aged 9, using current immunization strategies.
3. To use the three-dose immunization scheme established by the manufacturer.
4. To develop a communication strategy that allows informing the population on the adoption of this vaccine.
5. Logistic and operational aspects for the introduction of the vaccine must be guaranteed.
6. At the end of the first cohort, impact evaluation should be started.
7. Based on the previous points, the information generated by the MDEG, and its six subgroups will be sent to 
CONAVA for the feasibility analyses on the introduction of the dengue vaccine into the immunization scheme.
Table 4. MDEG recommendations for the introduction of a Dengue vaccine in Mexico.
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The criteria developed by the MDEG cover epidemiological, operational and communica-
tion issues that are applicable to other endemic regions in the world. It is important to notice 
that additionally to seroprevalence, these criteria include other measurable health impacts 
such as cumulative incidence, outbreak duration, proportion of severe cases, fatalities and 
hyperendemicity. The inclusion of these effects grants flexibility to the decision-makers 
while considering or not the adoption of dengue vaccines taking into account the particu-
lar characteristics and resources of the region. Having additional criteria is an advantage, 
since seroprevalence studies are very expensive and time-consuming, while basic data on 
disease burden using confirmed cases are usually available for the vast majority of health 
systems.
Simultaneously to the anticipatory introduction exercise, the Mexican National Regulatory 
Agency (COFEPRIS—National Commission for the Protection of Health Risks) began the 
licensing process for the CYD-TDV dengue vaccine. As stated in international protocols, 
COFEPRIS followed a scrupulous evaluation process that included the vaccine’s safety, effi-
cacy and quality of the candidate vaccine and, according to the country’s regulatory criteria. 
Although independent, these proceedings and those performed by the MDEG were not sepa-
rately carried out, since representatives of the two bodies met regularly in order to feedback 
from each other’s analyses. This feedback helped both parts to align their criteria, sources 
and information, and also contributed to optimize procedures while shortening the time for 
discussions. At the end of the registration processes, COFEPRIS issued a favorable resolution 
granting the licensure in December 2015 (Figure 2).
Having obtained the licensure for marketing the vaccine in the private sector, the next natural 
step is the procedure for the adoption of the vaccine as a health policy. It is now the respon-
sibility of the National Vaccination Council (CONAVA—Consejo Nacional de Vacunación) to 
decide if, when and how to introduce the new dengue vaccine in Mexico. The final MDEG 
Figure 2. Processes of licensure and adoption as a public health policy.
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recommendations were presented to the Council after the vaccine was licensed, and the pro-
posed criteria were adopted as the basis for the document published as the interim policy 
regarding the CYD-TDV vaccine. The policy establishes a series of criteria for introduction 
of the vaccine by public health institutions (Table 5). At this point, the only remaining crite-
rion to be fulfilled is the inclusion of CYD-TDV in the National Basic Catalogue of Medicinal 
Products, which has to be authorized by the General Health Council (Consejo de Salubridad 
General), the nation’s top authority in Public Health matters.
The introduction of a tetravalent dengue vaccine as a public policy is to be considered under the following 
conditions:
I. To fulfill at least four, out of the following six epidemiological criteria:
a. Population of states, municipalities or localities must have a demonstrable seroprevalence desirably 
equal or higher than 60%.
b. Cumulative incidence above the national mean, during at least one of the last 5 years.
c. Laboratory-confirmed cases of Dengue for at least 20 continuous weeks, during the last year.
d. Annual proportion of severe dengue equal or higher than 1% considering total notified cases.
e. At least one fatality recorded during the last 5 years.
f. Co-circulation of at least two serotypes and/or circulation of serotype 3 and/or 4.
II. To be applied in population aged 9–16.
III. To be applied using a three-dose immunization scheme: 0, 6 and 12 months, subcutaneously.
IV. To ensure sufficient budget in order to guarantee the acquisition of the three-dose scheme for the cohorts to be 
immunized.
V. To guarantee financial capacity for logistics, human and operational resources for vaccine introduction.
VI. To develop a social communication strategy that allows informing the population on the introduction of this 
vaccine.
VII. To develop a nominal registry of vaccinated individuals, preferably with an electronic vaccination card.
VIII. The vaccine must be included in the Mexican basic catalogue of medicinal products.
IX. The vaccine will not be universally applied in the country.
X. States and social welfare institutions that wish to introduce the vaccine must define their strategies through 
their State Vaccination Councils, and present them to the national normative bodies for validation, in order to 
guarantee the compliance of the previously described conditions. Final approval must be obtained from the 
National Vaccination Council (CONAVA) and include all health institutions to comply with normative frame in 
order to guarantee notification and follow-up of adverse effects following immunization (AEFI), and the impact 
evaluation that includes cases, hospital admissions and averted deaths at the end of the first vaccination cohort. 
Vaccination strategy must be performed in a comprehensive manner, meaning that all public health institutions 
in the state should introduce the vaccine simultaneously.
XI. Seroprevalence studies for the target group are proposed, after assessing budgetary and operational feasibility.
XII. Resources for acquiring the vaccine must not be taken from the budget of the National Dengue Program or have 
any impact on the total budget allocated to health institutions, considering the budget of the year immediate 
prior to the vaccine introduction.
Table 5. National Vaccination Council’s criteria for the introduction of a Dengue vaccine in Mexico [37].
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4. Rationale for the adoption of a dengue vaccine as a public health 
policy
4.1. The paradigm shift
Existing epidemiological evidence shows that current surveillance and preventive and con-
trol measures are just not enough to reverse the currently increasing tendency of disease 
burden caused by DENV infection [8]. Newly recognized factors such as the contribution 
of human mobility on dengue transmission, its impact on control interventions [38] and the 
threats posed by the recent emergence of zika, chikungunya, and other VTDs are also impor-
tant arguments to consider. To be able to curb the tendencies, vector control strategies need to 
evolve and adapt to new knowledge and technological developments in a way that has never 
occurred in the past but that is imperative in the face of the current challenges.
As discussed in this chapter, development and introduction of a dengue vaccine are a com-
plex, challenging and demanding process for public health systems that requires the partici-
pation of all relevant actors. To finally have a safe and effective vaccine against this disease is 
a major breakthrough in the prevention and control of one of the most important VTD in the 
world, therefore, the necessity of health systems in endemic areas to be prepared for the adop-
tion of this technology according to their particular needs and epidemiological characteristics.
Having achieved this milestone, the challenges now lie in operational aspects for the intro-
duction into immunization schemes and public health strategies. Dengue vaccines have 
unique characteristics that make them different to other existing vaccines. For this reason it 
is required that health personnel and general public have access to complete reliable infor-
mation to understand the indications, capacities and limitations of this vaccine, and more 
important, to recognize this tool as an integral piece of dengue control strategy. In order to 
facilitate this process, it is desirable to develop introduction guidelines for specific topics such 
as the vaccine, application procedures, surveillance, and mass communication among others.
As a theoretical argument, it is valid to expect that a vaccine is completely reliable, efficacious 
and safe, but in real life, vaccines are usually adopted considering a balance between posi-
tive and adverse effects. However, in reference to the development of this new vaccine, it has 
been recognized by leading experts in dengue that “the era when most vaccines provided efficacy 
well beyond 90% is over. Many of the more recently developed vaccines only provide partial efficacy. 
Although vaccines are typically licensed on the basis of demonstrated efficacy, the ultimate goal of vac-
cination goes far beyond efficacy” [39].
The availability of a licensed, safe and efficacious vaccine provides VTD prevention and control 
programs with a new tool to be added to the current arsenal. Vector control strategies should 
no longer be considered as the sole preventive measures for dengue control, and it must be 
acknowledged that the development of dengue vaccines constitutes an important milestone 
that needs to be thoroughly evaluated in scientific terms and not with dogmatic positions.
Unnecessary delays in the introduction of CYD-TDV or any other dengue vaccine will have 
important consequences for the population of endemic areas. The first and most obvious is 
the persistence of the current epidemiological trend with more and more people suffering 
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from the disease and its consequences. Not introducing the vaccine will obstruct individuals 
from their right to obtain the protective benefits of the vaccine, benefits not currently pro-
vided by any other available measure.
Lacking hosts other than humans, being transmitted only by a specific and highly anthro-
pophilic mosquito species, and being a predominantly urban disease, dengue elimination is 
theoretically feasible, but it requires a paradigm shift in prevention and control strategies that 
integrates additional approaches such as the introduction of a new vaccine to existing policies 
and approaches.
5. Conclusions
The use of vaccines has been critical in the control and eventual eradication of major epidemic 
diseases, especially those with direct transmission. Vaccines for VTDs such as the yellow fever 
vaccine have proven their value both as preventive tools and as control measures in the case 
of outbreaks.
The newly available dengue vaccine and those currently under development are valuable tools 
intended to complement, not replace, current and future dengue prevention and control strate-
gies [40]. In the operational scope, this integration needs to be performed in a comprehensive 
manner in order to maximize the positive effects of individual measures [41], and to avoid 
the collateral effects of excessive usage of those currently available [42]. This approach will 
undoubtedly be essential for reaching the WHO’s strategic goal of 25% reduction in morbidity 
and 50% reduction in mortality due to dengue by 2020 [43]. Delaying decisions regarding the 
introduction of dengue vaccines could have important public health and economic implications.
Just as with any other vaccine, the most important safety and efficacy evaluation will begin 
once it is used in a real-life environment, when the vaccine must demonstrate a measurable 
impact on the disease. This impact can be estimated through changes in age-stratified indica-
tors such as total number of cases, incidence or lethality. Additionally, the introduction of a 
new vaccine needs to further evaluate its safety through pharmacosurveillance in order to 
identify any adverse effects attributable to the vaccine. With proper follow-up, it will be pos-
sible then to define the real usefulness of the vaccine as a public health measure.
As an exercise, the roadmap here described has provided valuable experiences and the expected 
results in a short period. The formation of National Expert Groups for the analysis of feasibility 
for the introduction of dengue vaccines was fundamental for achieving such goals and should 
be a requisite for any country willing to explore the adoption on any existing or future vaccines.
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